Weight loss is a large topic of conversation for people around the country. Many people struggle with losing weight, but they want to improve their well-being, confidence, and most importantly, their health. Fitness instructors, weight loss clinics, and wellness spas all have specialized programs that address various aspects of weight loss. Semaglutide and Tirzepatide injections are among the newer interventions to accelerate weight loss.
Castle Rock Regenerative Health is offering tailored weight loss programs incorporating these medications under the guidance of Dr. Scott™️, who meets with all of his patients via telehealth or in-person appointments. When used appropriately and in tandem with proper diet, exercise, and guidance from a skilled medical provider, both Semaglutide and Tirzepatide have proven to be a successful and safe way to lose weight and feel more like “you.”
What are Semaglutide and Tirzepatide?
Semaglutide (Ozempic® and Wegovy®) and Tirzepatide are FDA-approved injectable weight-loss medications that have swept the weight-loss industry. These medications were originally developed to help those with type 2 diabetes manage their conditions and symptoms. Both Semaglutide and Tirzepatide help effectively and sustainably reduce body weight over time by controlling an individual’s appetite. These additional weight loss benefits make them appealing solutions for non-diabetic patients as well.
How Do Semaglutide and Tirzepatide Work?
Semaglutide and Tirzepatide are once-weekly injections administered into your abdominal tissue. Both Semaglutide and Tirzepatide mimic hunger hormones and contribute to an overall reduction in food intake and delaying gastric emptying. Both are very effective at managing weight loss in individuals with and without type 2 diabetes.
Semaglutide is a selective GLP-1 (Glucagon-Like Peptide-1) receptor agonist. This means that this medication mimicks the “I’m full” hormone we naturally have when our stomach tells our brains that we can’t eat another bite.
Tirzepatide is a GLP-1 and GIP (Glucose-Dependent Insulinotropic Polypeptide) agonist and sends similar signals to the brain regarding appetite. Tirzepatide has also been studied to help lower LDL cholesterol and triglycerides and improve blood pressure.
What Kind Of Side Effects Could I Experience?
Both Semaglutide and Tirzepatide have some GI-related symptoms, but the vast majority of patients do not experience any symptoms other than a reduction in appetite. Symptoms are primarily experienced if an individual is going through an increase in medication dosage. These side effects can sometimes include diarrhea, nausea, heartburn, headaches, and constipation.
When Do I Start Seeing Results?
Each person is unique in their weight loss journey. Many of our patients start to see results in as little as one to two weeks, though Semaglutide and Tirzepatide studies show that these medications are safe to incorporate into long-term weight loss programs.
While Semaglutide and Tirzepatide are effective at managing weight on their own, we also recommend and encourage making nutritious diet choices and incorporating a healthy exercise routine. Castle Rock Regenerative Health will help you meet your health goals holistically, including weight loss.
Which Medication Is Right For Me?
Semaglutide and Tirzepatide are safe and effective options for people who have losing weight as one of their primary health goals. At Castle Rock Regenerative Healthcare, Dr. Scott™️ is a renowned medical professional specializing in advanced regenerative health and understands that each person is unique.
At Castle Rock Regenerative Healthcare, we offer free consultations with Dr. Scott™️ to discuss which weight loss medications are the best for you! Both in-person appointments and telehealth appointments are available and can be scheduled here.
The starting medication dose is $200 per month, and we also have a special discount for new patients. Use code “CR20” to get 20% off and $25 shipping for your first order!
Sources:
- National Library of Medicine: PubMed: Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial
- National Library of Medicine: PubMed: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomized, multicentre, placebo-controlled, phase 3 trial
- National Library of Medicine: PubMed: Safety of Semaglutide
- National Library of Medicine: PubMed: Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- National Library of Medicine: PubMed: Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomized, phase 3 trial
- National Library of Medicine: PubMed: Tirzepatide: A Systematic Update
